SCHEMBL184523

SCHEMBL184523

O=C(Cl)CN1CCCC1=O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.66
HTT P42858 1/20 0.51
KMT2A Q03164 3/20 0.49
PIK3CD O00329 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.44
LMNA P02545 2/20 0.44
CYP1A2 P05177 1/20 0.43
CHRM2 P08172 1/20 0.43
CHRM4 P08173 1/20 0.43
CHRM5 P08912 1/20 0.43
CYP2D6 P10635 1/20 0.43
CHRM1 P11229 1/20 0.43
CYP2C9 P11712 1/20 0.43
CHRM3 P20309 1/20 0.43
CYP2C19 P33261 1/20 0.43
ALDH1A1 P00352 2/20 0.43
MEN1 O00255 1/20 0.42
PKM P14618 1/20 0.42
ATAD2 Q6PL18 1/20 0.42
CECR2 Q9BXF3 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL948990 0.81 TSHR (0.68) TSHRHTTKMT2APIK3CDSMN1; SMN2
SCHEMBL2449756 0.80 TSHR (0.52) TSHRHTTKMT2APIK3CDSMN1; SMN2
SCHEMBL1328881 0.80 TSHR (0.61) TSHRHTTKMT2APIK3CDSMN1; SMN2
SCHEMBL6935107 0.79 TSHR (0.66) TSHRHTTKMT2APIK3CDLMNA
Piracetam SCHEMBL6140872 0.79 TSHR (1.00) TSHRHTTKMT2APIK3CDSMN1; SMN2
SCHEMBL7769433 0.79 TSHR (0.66) TSHRHTTKMT2APIK3CDSMN1; SMN2
Piracetam SCHEMBL20172 0.79 TSHR (1.00) TSHRHTTKMT2APIK3CDSMN1; SMN2
SCHEMBL18455388 0.79 TSHR (0.66) TSHRHTTKMT2APIK3CDSMN1; SMN2
SCHEMBL11239159 0.78 TSHR (0.63) TSHRHTTKMT2APIK3CDLMNA
Dupracetam SCHEMBL1814646 0.78 TSHR (0.63) TSHRHTTKMT2APIK3CDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0089900-B1 NEW N-((2-OXO-1-PYRROLIDINYL)ACETYL)PIPERAZINES, THE METHODS OF PRODUCING SUCH NEW COMPOUNDS AND THEIR SALTS AS WELL AS PHARMACEUTICAL PREPARATIONS FOR THERAPEUTIC USE CONTAINING THESE COMPOUNDS OR SALTS PRODES S.A. (ES) 1985-12-27 EP claimed
EP-0089900-A1 New N-((2-oxo-1-pyrrolidinyl)acetyl)piperazines, the methods of producing such new compounds and their salts as well as pharmaceutical preparations for therapeutic use containing these compounds or salts PRODES S.A. (ES) 1983-09-28 EP claimed
US-9090597-B2 Pyrazolone derivatives as PDE4 inhibitors TAKEDA GMBH (DE) 2015-07-28 US disclosed
US-20140378509-A1 PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS TAKEDA GMBH (DE) 2014-12-25 US disclosed
US-8865745-B2 Pyrazolone derivatives as PDE4 inhibitors TAKEDA GMBH (DE) 2014-10-21 US disclosed
US-20130012544-A1 PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS NYCOMED GMBH (DE) 2013-01-10 US disclosed
US-8304436-B2 Pyrazolone derivatives as PDE4 inhibitors NYCOMED GMBH (DE) 2012-11-06 US disclosed
EP-2508520-A1 Pyrazolone-derivatives as PDE4 inhibitors Nycomed GmbH (DE) 2012-10-10 EP disclosed
EP-2402330-A1 Pyrazolone-derivatives as PDE4 inhibitors Nycomed GmbH (DE) 2012-01-04 EP disclosed
EP-2148876-B1 PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS NYCOMED GMBH (DE) 2011-09-28 EP disclosed
US-20100120757-A1 PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS NYCOMED GMBH (DE) 2010-05-13 US disclosed
EP-2148876-A1 PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS Nycomed GmbH (DE) 2010-02-03 EP disclosed
WO-2008138939-A1 PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS NYCOMED GMBH (DE) 2008-11-20 WO disclosed
EP-0089900-B1 NEW N-((2-OXO-1-PYRROLIDINYL)ACETYL)PIPERAZINES, THE METHODS OF PRODUCING SUCH NEW COMPOUNDS AND THEIR SALTS AS WELL AS PHARMACEUTICAL PREPARATIONS FOR THERAPEUTIC USE CONTAINING THESE COMPOUNDS OR SALTS PRODES S.A. (ES) 1985-12-27 EP disclosed
US-4324787-A 2-Oxo-1-pyrrolidineacetic acid compounds and their medicinal use TROPONWERKE GMBH & CO., KG (DE) 1982-04-13 US disclosed
US-4216221-A MNEMIC PROCESSES U C B, SOCIETE ANONYME (BE) 1980-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120757-A1 PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS PDE4A, PDE4B, PDE3A TSHR 1823/4885HTT 4693/4885KMT2A 3447/4885
US-20130012544-A1 PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS PDE4A, PDE4B, PDE5A TSHR 3640/4885HTT 4338/4885KMT2A 2302/4885
US-20140378509-A1 PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS PDE4A, PDE4B, PDE4D TSHR 4394/4885HTT 4777/4885KMT2A 2120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.